MMWR Morb Mortal Wkly Rep. 2002 Nov 8;51(44):998-9.
Reports of fatal and severe liver injury associated with treatment of latent tuberculosis infection (LTBI) with the drug combination rifampin and pyrazinamide (RZ) prompted CDC to issue revised guidelines for the use of this regimen on August 31, 2001. To determine if these revised guidelines were effective in reducing morbidity and mortality, CDC has continued to collect reports on adverse effects associated with this regimen. This update summarizes the results of this ongoing investigation.
有报告称，使用利福平与吡嗪酰胺（RZ）联合用药治疗潜伏性结核感染（LTBI）会导致致命性和严重性肝损伤，这促使美国疾病控制与预防中心（CDC）于2001年8月31日发布了关于该治疗方案使用的修订指南。为确定这些修订指南是否能有效降低发病率和死亡率，CDC持续收集有关该治疗方案不良反应的报告。本更新内容总结了这项正在进行的调查结果。
